Skip to main content
main-content

Spondyloarthropathies

Clinical trials

24-07-2018 | Psoriatic arthritis | Article

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: Week 52 results from SPIRIT-P2

Genovese MC et al. Rheumatology (Oxford) 2018: key182. doi: 10.1093/rheumatology/key182

25-06-2018 | Psoriatic arthritis | Article

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

Gottlieb AB et al. Rheumatology (Oxford) 2018: key161. doi: 10.1093/rheumatology/key161

29-06-2018 | Adalimumab biosimilar | Article

Similar pharmacokinetics of the adalimumab (Humira®) biosimilar BI 695501 whether administered via subcutaneous autoinjector or prefilled syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, randomized, open-label, parallel-group trials

The authors present two phase 1 studies comparing the pharmacokinetics, safety, and immunogenicity of adalimumab biosimilar BI 695501 delivered via autoinjector versus prefilled syringe.

Ramael S et al. Rheumatol Ther 2018. doi: 10.1007/s40744-018-0119-1

Similar pharmacokinetics of the adalimumab (Humira®) biosimilar BI 695501 whether administered via subcutaneous autoinjector or prefilled syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, randomized, open-label, parallel-group trials

The authors present two phase 1 studies comparing the pharmacokinetics, safety, and immunogenicity of adalimumab biosimilar BI 695501 delivered via autoinjector versus prefilled syringe [read more].
Ramael S et al. Rheumatol Ther 2018. doi: 10.1007/s40744-018-0119-1

07-06-2018 | Psoriatic arthritis | Article

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: Results from the FUTURE 2 study

McInnes IB et al. Arthritis Res Ther 2018; 20: 113. doi: 10.1186/s13075-018-1610-3

04-04-2018 | Psoriatic arthritis | Article

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: Results of the randomized, placebo-controlled PALACE 4 trial

Wells AF et al. Rheumatology (Oxford) 2018; Advance online publication. doi: 10.1093/rheumatology/key032

17-03-2018 | Secukinumab | Article

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomized, double-blind, phase III FUTURE 5 study

Mease P et al. Ann Rheum Dis 2018; Advance online publication. doi: 10.1136/annrheumdis-2017-212687

28-11-2017 | Psoriatic arthritis | Article

A resistance exercise program improves functional capacity of patients with psoriatic arthritis: A randomized controlled trial

The results of this study demonstrate that resistance exercises are effective in improving functional capacity, disease activity, and the general quality of life of patients with psoriatic arthritis.

Roger-Silva D et al. Clin Rheumatol 2017. doi: 10.1007/s10067-017-3917-x

07-07-2017 | Psoriatic arthritis | Article

Elderly psoriatic arthritis patients on TNF-α blockers: Results of an Italian multicenter study on minimal disease activity and drug discontinuation rate

The results of this study suggest that tumor necrosis factor-alpha blockers are effective and safe in elderly patients with psoriatic arthritis and age should not be considered a limitation to their use.

Costa L, Lubrano E, Ramonda R et al. Clin Rheumatol 2017;36:1797–1802. doi:10.1007/s10067-017-3697-3

08-08-2017 | Psoriatic arthritis | Article

Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis

This meta-analysis finds that apremilast, secukinumab, and ustekinumab are all more efficacious than placebo; however, there are no significant differences in the efficacy and safety between the drugs.

Song GG, Lee YH. Z Rheumatol 2017. doi:10.1007/s00393-017-0355-8

07-03-2017 | Psoriatic arthritis | Article

Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry

Harrold et al. perform a retrospective analysis of observational data collected on patients with psoriatic arthritis to further understanding of the factors associated with therapy persistence in patients.

Harrold LR et al. Clin Rheumatol 2017;36:895–901. doi:10.1007/s10067-017-3593-x

24-08-2016 | Axial spondyloarthritis | Article

Web-based physiotherapy for people with axial spondyloarthritis (WEBPASS) – a study protocol

Introducing a study to assess adherence to a 12-month individualized web-based physiotherapy program for people with axial spondyloarthritis. 

Paul L et al. BMC Musculoskelet Disord 2016;17:360. doi:10.1186/s12891-016-1218-1

image credits